About
About NAD+ Nasal Spray
NAD+ nasal spray delivers nicotinamide adenine dinucleotide across the nasal mucosa, providing an alternative to injectable administration that many individuals find more convenient for ongoing daily use. The nasal route allows the coenzyme to enter circulation while potentially facilitating proximity to central nervous system tissue via olfactory pathways, though the precise pharmacokinetics of nasal NAD+ in humans are still being characterized.
NAD+ is a coenzyme central to cellular energy metabolism, DNA repair signaling, and the activity of sirtuins -- a family of proteins that have attracted considerable research attention in the context of aging biology. NAD+ levels decrease with age, and there is growing scientific interest in whether supporting these levels through supplementation may have meaningful effects on cellular health and resilience. The nasal spray formulation offers a high-concentration, low-volume delivery option for daily or as-directed use.
Usage is determined by a licensed provider following an online visit. Typical protocols involve one to several sprays per nostril once or twice daily, adjusted based on individual response and provider guidance. The nasal spray is generally well-tolerated; some users note mild transient nasal irritation. Because it avoids the intravenous or subcutaneous route, it is often considered a practical option for maintenance dosing between periodic injectable sessions.
NAD+ nasal spray may be appropriate for adults who prefer a non-injectable format, those maintaining a longevity protocol established with a provider, or individuals new to NAD+ supplementation who want to begin with a less invasive route. It is not a replacement for evaluation of underlying fatigue or metabolic concerns.
This product is compounded by a licensed 503A pharmacy and dispensed only after a provider review. It is not an FDA-approved drug product. Individual responses to NAD+ supplementation vary, and benefits described in the literature are based on preliminary research.
